ELEKTA’S BOARD DECIDES ON REPURCHASE OF OWN SHARES

ELEKTA'S BOARD DECIDES ON REPURCHASE OF OWN SHARES

PRESS RELEASE			
Stockholm, Sweden, March 9, 2007 

The Board of Directors of Elekta AB (publ) has decided to utilize the authorization the Board received from the Annual General Meeting to repurchase shares in the company.

Elekta's distribution policy is to distribute 20 percent or more of net profits to shareholders in the form of dividends, share repurchases or comparable measures. Elekta's Annual General Meeting on September 20, 2006 resolved to authorize the Board to decide on the acquisition of a maximum of 10 percent of the total number of shares in the company.

The Board today decided to exercise the mandate and to authorize the executive management to initiate, on appropriate occasions, the repurchase of shares in an amount of SEK 100 M, but maximized to 900.000 shares.

As of today, Elekta does not own any of its own shares. A repurchase of 900.000 shares is corresponding to 1.0 percent of the total number of outstanding shares in the company. Elekta intends to propose to the AGM that repurchased shares are cancelled. 

Purchases will be made on the Stockholm Stock Exchange and to a price within the spread at the time of purchase. Purchases can be made during the time until next Annual General Meeting.


For further information, please contact:


Peter Ejemyr, Group VP Corporate Communications
Tel: +46 733 611 000 (mobile), e-mail: peter.ejemyr@elekta.com

About Elekta
Elekta is an international medical-technology Group, providing meaningful clinical solutions, comprehensive information systems and services for improved cancer care and management of brain disorders. All of Elekta's solutions employ non-invasive or minimally invasive techniques and are therefore clinically effective, gentle on the patient and cost-effective. 

Clinical solutions include among others Leksell Gamma Knife® for non-invasive treatment of brain disorders and Elekta Synergy® for image guided radiation therapy (IGRT). Following the acquisition of IMPAC Medical Systems Inc. in April 2005, the Elekta Group is the world's largest supplier of oncology software. 

Elekta's systems and solutions are used at over 4,000 hospitals around the world to treat cancer and manage clinical operations as well as to diagnose and treat brain disorders, including tumors, vascular malformations and functional disorders. 

With approx. 2,000 employees, Elekta's corporate headquarter is located in Stockholm, Sweden and the company is listed on the Stockholm Stock Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.